Biogen Appoints Anabella Villalobos Senior Vice President, Biotherapeutic & Medicinal Sciences
July 31 2017 - 9:00AM
Business Wire
Biogen (NASDAQ:BIIB) today announced the appointment of
Anabella Villalobos, Ph.D., as senior vice president,
Biotherapeutic & Medicinal Sciences (BTMS). Dr. Villalobos will
lead Biogen’s BTMS organization in the delivery of high-quality,
differentiated molecules to the clinic. She will report to Michael
Ehlers, M.D., Ph.D., executive vice president, Head of Research and
Development.
“We are excited to have Anabella Villalobos join us at Biogen,”
said Dr. Ehlers. “Anabella is a world-class drug hunter, a proven
leader in medicinal sciences, and a champion of scientific
innovation. Her experience in neuroscience and passion for drug
discovery will help us create and advance the next generation of
breakthrough medicines.”
Dr. Villalobos joins Biogen from Pfizer Worldwide Research and
Development where she most recently served as Vice President and
Head of Medicinal Synthesis Technologies. With over 25 years of
industry experience in the areas of neuroscience and medicinal
chemistry, she has been instrumental in the development of clinical
candidates for Alzheimer’s disease, Parkinson’s disease,
schizophrenia, and pain.
“Biogen has been an absolute pacesetter in developing
breakthrough neurology medicines in the forms of biologics, small
molecules, and new anti-sense oligonucleotide therapies for
patients.” said Dr. Villalobos. “I am honored to lead
Biotherapeutic & Medicinal Sciences, and I look forward to
accelerating our neuroscience discovery to find new approaches for
the most challenging conditions of the brain.”
Before joining industry, Dr. Villalobos received a BS in
Chemistry from the University of Panama, a Ph.D. in Medicinal
Chemistry from The University of Kansas, and synthetic organic
chemistry training at Yale University as a National Institutes of
Health Postdoctoral Fellow.
About BiogenThrough cutting-edge science and medicine,
Biogen discovers, develops and delivers worldwide innovative
therapies for people living with serious neurological and
neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in
biotechnology, and today the company has the leading portfolio of
medicines to treat multiple sclerosis; has introduced the first and
only approved treatment for spinal muscular atrophy; and is at the
forefront of neurology research for conditions including
Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral
sclerosis. Biogen also manufactures and commercializes biosimilars
of advanced biologics. For more information, please visit
www.biogen.com. Follow us on social media – Twitter, LinkedIn,
Facebook, YouTube.
Biogen Safe HarborThis press release contains
forward-looking statements, made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
including statements relating to Biogen’s business activities and
potential of our commercial business and pipeline programs. These
forward-looking statements may be accompanied by words such as
“aim,” “anticipate,” “believe,” “could,” “estimate,” “except,”
“forecast,” “intend,” “may,” “plan,” “potential,” “possible,”
“will” and other words and terms of similar meaning. You should not
place undue reliance on these statements. Drug development and
commercialization involve a high degree of risk, and only a small
number of research and development programs result in
commercialization of a product.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including, without limitation: risks relating to
management and key personnel changes; failure to compete
effectively; difficulties in obtaining and maintaining adequate
coverage, pricing and reimbursement for our products; potential
future healthcare reforms; the occurrence of adverse safety events;
failure to protect and enforce our data, intellectual property and
other proprietary rights and uncertainties relating to intellectual
property claims and challenges; uncertainty of success in
developing, licensing or acquiring other product candidates or
additional indications for existing products; delay in approval of
our drug candidates; product liability claims; and third party
collaboration risks. The foregoing sets forth many, but not all, of
the factors that could cause actual results to differ from our
expectations in any forward-looking statement. Investors should
consider this cautionary statement, as well as the risk factors
identified in Biogen’s most recent annual or quarterly report and
in other reports Biogen has filed with the U.S. Securities and
Exchange Commission. These statements are based on our current
beliefs and expectations and speak only as of the date of this
press release. We do not undertake any obligation to publicly
update any forward-looking statements, whether as a result of new
information, future developments or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170731005551/en/
BiogenMatt Fearer,
+1-781-464-3260public.affairs@biogen.comorBenjamin Strain,
+1-781-464-2442IR@biogen.com
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2023 to Apr 2024